DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Small Study / Early Comparative Evidence
Interim ELEVATE-PD data on 111 Parkinson’s patients switching from other levodopa formulations to Crexont (extended-release carbidopa/levodopa) showed >3 hours daily increase in “good on” time and >3 hours decrease in off time within six weeks. The trial is open-label, manufacturer-conducted, and ongoing.
Clinical Considerations
- Improvements appeared regardless of prior levodopa formulation, including instant-release, COMT-inhibitor combinations, and Rytary.
- Open-label design and sponsor involvement limit interpretation, particularly for patient-reported on/off time outcomes.
- Motor fluctuation reduction and standard motor severity measures showed directionally consistent improvement alongside the on-time gains.
- Safety data tracked Crexont’s known profile from the 2024 FDA approval; no new signals reported in the interim cut.
Practice Applications
- Recognize the data are interim, open-label, and sponsor-conducted, not pivotal evidence.
- Consider Crexont as a switch option for patients with motor fluctuations inadequately controlled on other levodopa formulations.
- Interpret patient-reported on/off time gains alongside objective motor scales rather than in isolation.
- Monitor the full ELEVATE-PD readout and any independent comparative data before broader practice changes.
More on Parkinson’s Disease
